pomalidomide has been researched along with Agnogenic Myeloid Metaplasia in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 17 (89.47) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ali, HK; Barkas, N; Barosi, G; Buck, G; Chowdhury, O; Devos, T; Gale, RP; Gisslinger, H; Hamblin, A; Jiang, Q; Kiladjian, JJ; McMullin, MF; Mead, AJ; Mesa, R; O'Sullivan, J; Passamonti, F; Ribrag, V; Schiller, G; Tefferi, A; Vannucchi, AM; Wang, G; Zhong, J; Zhou, D | 1 |
| Cervantes, F; Martinez-Trillos, A | 1 |
| Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Pierce, S; Quintas-Cardama, A; Shastri, A; Verstovsek, S; Zhou, L | 1 |
| Guglielmelli, P; Vannucchi, AM | 1 |
| Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S | 1 |
| Andrei, M; Sindhu, H; Wang, JC | 1 |
| Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L | 1 |
| Birgegård, G | 1 |
| Al-Ali, HK; Barosi, G; Devos, T; Gale, RP; Gisslinger, H; Jiang, Q; Kiladjian, JJ; McMullin, MF; Mesa, R; Passamonti, F; Reiser, D; Ribrag, V; Schiller, G; Tefferi, A; Vannucchi, AM; Zhong, J; Zhou, D | 1 |
| Benner, A; Blau, IW; Döhner, H; Döhner, K; Gattermann, N; Grießhammer, M; Hebart, H; Heidel, FH; Hochhaus, A; Jost, E; Kreipe, H; Platzbecker, U; Reiter, A; Schafhausen, P; Schlenk, RF; Stegelmann, F; Teleanu, V; Verbeek, W; Waller, C; Werner, M | 1 |
| Ross, DM | 1 |
| Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y | 1 |
| Hogan, WJ; Hussein, K; Litzow, MR; Mesa, RA; Pardanani, AD; Schwager, S; Tefferi, A; Wu, W | 1 |
| Lacy, MQ; Rajkumar, SV | 1 |
| Begna, KH; Hogan, WJ; Litzow, MR; McClure, RF; Mesa, RA; Pardanani, A; Tefferi, A | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Begna, K; Finke, C; Lasho, T; Pardanani, A; Tefferi, A | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Begna, KH; Hanson, CA; Hogan, WJ; Litzow, MR; Mesa, R; Pardanani, A; Tefferi, A | 1 |
5 review(s) available for pomalidomide and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Myelofibrosis: an update on current pharmacotherapy and future directions.
Topics: Age Factors; Androgens; Anemia; Humans; Immunologic Factors; Janus Kinase 2; Mutation; Nitriles; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Radiotherapy; Splenomegaly; Stem Cell Transplantation; Thalidomide | 2013 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Topics: Cytokines; Humans; Immunologic Factors; Multiple Myeloma; Neovascularization, Pathologic; Primary Myelofibrosis; Signal Transduction; Thalidomide | 2010 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
10 trial(s) available for pomalidomide and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Primary Myelofibrosis; Prospective Studies; Thalidomide; Treatment Outcome | 2013 |
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferative Disorders; Neoplasms; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Topics: Aged; Aged, 80 and over; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Male; Middle Aged; Myeloproliferative Disorders; Phenotype; Primary Myelofibrosis; Thalidomide; Treatment Outcome; Workflow | 2017 |
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Topics: Aged; Aged, 80 and over; Alleles; Biomarkers; Chromosome Banding; Female; Humans; Immunologic Factors; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Phenotype; Prednisolone; Primary Myelofibrosis; Thalidomide; Treatment Outcome | 2017 |
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Double-Blind Method; Female; Glucocorticoids; Hematinics; Humans; Immunologic Factors; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Prospective Studies; Thalidomide | 2009 |
Phase1/-2 study of Pomalidomide in myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anti-Inflammatory Agents; Female; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Prednisolone; Primary Myelofibrosis; Thalidomide | 2010 |
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Topics: Aged; Aged, 80 and over; Anemia; Basophils; Erythrocyte Transfusion; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Primary Myelofibrosis; Thalidomide | 2011 |
Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Chemokine CCL2; Cytokines; Female; Humans; Interleukin-15; Interleukin-8; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Mutation; Predictive Value of Tests; Primary Myelofibrosis; Receptors, Interleukin-2; Thalidomide; Treatment Outcome | 2011 |
Long-term outcome of pomalidomide therapy in myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
4 other study(ies) available for pomalidomide and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Topics: Disease Management; Disease Susceptibility; Erythrocyte Transfusion; Humans; Mutation; Myeloproliferative Disorders; Primary Myelofibrosis; Spliceosomes; Thalidomide; Treatment Outcome | 2021 |
Struggling with myelofibrosis-associated anemia.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Primary Myelofibrosis; Thalidomide | 2013 |
Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Humans; Leukocyte Count; Male; Nitriles; Platelet Count; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Quality of Life; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Responses to pomalidomide and placebo in myelofibrosis-related anaemia.
Topics: Anemia; Humans; Immunologic Factors; Primary Myelofibrosis; Thalidomide | 2017 |